Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 16;7:13249. doi: 10.1038/s41598-017-13320-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

In vivo MRI potential of MDNPs. (A,B,C,D) MRI images of the tumors in the control group and the group treated with folic acid-conjugated MDNPs (FA-MDNPs) before and after injection of the respective solutions. A distinct darkening of the tumor was observed in the group treated with MDNPs post injection. (E) Significant T2 signal intensity drop was observed in the case of FA-MDNPs indicating greater negative contrast due to the presence of iron oxide in the tumor (n = 4). (F,G,H) Prussian blue staining on the tumors (10x magnification). More blue regions (arrows) seen in the FA-MDNPs group indicating presence of greater amount of iron oxide in the tumor.